• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PGP9.5 as a prognostic factor in pancreatic cancer.

作者信息

Tezel E, Hibi K, Nagasaka T, Nakao A

机构信息

Department of Surgery II, Nagoya University School of Medicine, Japan.

出版信息

Clin Cancer Res. 2000 Dec;6(12):4764-7.

PMID:11156232
Abstract

The expression of PGP9.5 was evaluated using immunohistochemistry in 69 resected ductal carcinomas of the pancreas and in normal pancreatic tissue. Overexpression did not seem to differ with histological type or pathological stage. A significant negative correlation was found between overexpression of PGP9.5 and postoperative survival. Multivariate analysis also suggested PGP9.5 along with tumor stage and extrapancreatic plexus invasion as strong predictors of the outcome. This study suggests that PGP9.5 expression may be used as a marker for predicting the outcome of resection-treated pancreatic cancer patients.

摘要

相似文献

1
PGP9.5 as a prognostic factor in pancreatic cancer.
Clin Cancer Res. 2000 Dec;6(12):4764-7.
2
High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker.肿瘤相关抗原RCAS1在胰腺导管腺癌中的高表达是一种不良预后标志物。
Int J Cancer. 2002 May 20;99(3):418-23. doi: 10.1002/ijc.10381.
3
Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.MAP4K4的表达与II期胰腺导管腺癌患者的预后较差相关。
Clin Cancer Res. 2008 Nov 1;14(21):7043-9. doi: 10.1158/1078-0432.CCR-08-0381.
4
L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.L1 细胞黏附分子(L1CAM)在癌症侵袭前沿的表达是胰腺导管腺癌的一种新的预后标志物。
J Surg Oncol. 2011 Jun 1;103(7):669-73. doi: 10.1002/jso.21880. Epub 2011 Feb 28.
5
The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.表皮生长因子受体在手术切除的胰腺癌中的预后和预测作用
Int J Mol Sci. 2016 Jul 8;17(7):1090. doi: 10.3390/ijms17071090.
6
Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas.半乳糖凝集素-3表达在胰腺导管腺癌中的临床病理意义
Clin Cancer Res. 2002 Aug;8(8):2570-5.
7
Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.埃兹蛋白过表达预示胰腺导管腺癌预后不良。
Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.
8
Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.Sineoculis homeobox homolog 1 蛋白过表达可作为胰腺导管腺癌的独立生物标志物。
Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.
9
Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.肿瘤上皮细胞波形蛋白表达与胰腺导管腺癌的结局。
Br J Cancer. 2011 Apr 12;104(8):1296-302. doi: 10.1038/bjc.2011.93. Epub 2011 Mar 29.
10
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.术前 CEA 和 CA 19-9 是可切除性胰腺导管腺癌患者生存的预后标志物——一项回顾性肿瘤标志物预后研究。
Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23.

引用本文的文献

1
Proteasomes and Ubiquitin C-Terminal Hydrolase L1 as Biomarkers of Tissue Damage and Inflammatory Response to Different Types of Injury-A Short Review.蛋白酶体和泛素C末端水解酶L1作为不同类型损伤的组织损伤和炎症反应生物标志物——简短综述
Life (Basel). 2025 Mar 6;15(3):413. doi: 10.3390/life15030413.
2
GFAP and UCHL1 in Non-traumatic SAH: The Story thus Far. A Systematic Review of the Literature.胶质纤维酸性蛋白(GFAP)和泛素羧基末端水解酶 L1(UCHL1)在非创伤性蛛网膜下腔出血(SAH)中的研究进展:系统文献回顾。
CNS Neurol Disord Drug Targets. 2024;23(11):1328-1344. doi: 10.2174/0118715273276472231116104549.
3
Nanoemulsion-Assisted siRNA Delivery to Modulate the Nervous Tumor Microenvironment in the Treatment of Pancreatic Cancer.
纳米乳剂辅助 siRNA 递送来调节神经肿瘤微环境治疗胰腺癌。
ACS Appl Mater Interfaces. 2022 Mar 2;14(8):10015-10029. doi: 10.1021/acsami.1c21997. Epub 2022 Feb 21.
4
Ubiquitin C-terminal hydrolase-L1 expression in non-small-cell lung cancer and its association with clinicopathological features and prognosis.泛素 C-末端水解酶-L1 在非小细胞肺癌中的表达及其与临床病理特征和预后的关系。
Virchows Arch. 2022 Mar;480(3):577-585. doi: 10.1007/s00428-021-03199-y. Epub 2021 Nov 10.
5
UCH-L1 and UCH-L3 regulate the cancer stem cell-like properties through PI3 K/Akt signaling pathway in prostate cancer cells.泛素羧基末端水解酶L1(UCH-L1)和泛素羧基末端水解酶L3(UCH-L3)通过PI3K/Akt信号通路调节前列腺癌细胞中癌症干细胞样特性。
Anim Cells Syst (Seoul). 2021 Oct 11;25(5):312-322. doi: 10.1080/19768354.2021.1987320. eCollection 2021.
6
UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology.UCHL1 作为乳腺癌的一个新靶点:细胞和化学生物学的新见解。
Br J Cancer. 2022 Jan;126(1):24-33. doi: 10.1038/s41416-021-01516-5. Epub 2021 Sep 8.
7
A novel c.-652C>T mutation in UCHL1 gene is associated with the growth performance in Yangzhou goose.UCHL1基因中的一个新的c.-652C>T突变与扬州鹅的生长性能相关。
Poult Sci. 2021 Jul;100(7):101089. doi: 10.1016/j.psj.2021.101089. Epub 2021 Mar 13.
8
Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention.人类恶性肿瘤中泛素蛋白酶体系统的失调:治疗干预的窗口
Cancers (Basel). 2021 Mar 25;13(7):1513. doi: 10.3390/cancers13071513.
9
Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer.泛素羧基末端水解酶与人类恶性肿瘤:对头颈部癌的新预后及治疗意义
Front Oncol. 2021 Jan 29;10:592501. doi: 10.3389/fonc.2020.592501. eCollection 2020.
10
Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion.一个家族中存在 Behr 综合征和肥厚型心肌病,伴有一个新的 UCHL1 缺失。
J Neurol. 2020 Dec;267(12):3643-3649. doi: 10.1007/s00415-020-10059-3. Epub 2020 Jul 12.